Altogether, these results show that MHC-II can be induced in tumor cells resistant to IFN-γ by co-treatment with inhibitors, which could ultimately turn MHC-II-negative into MHC-II-positive tumors and, therefore, potentially targetable by CD4+ T cell therapy. Here, IFNG is linked to neoplasm.